Novel Small‑Molecule Inhibitors Targeting KRAS Mutations in Pancreatic Cancer

Background

Pancreatic ductal adenocarcinoma (PDAC) accounts for roughly 90 % of pancreatic cancers and carries a dismal 5‑year survival of only 6‑10 %. Over 90 % of PDAC tumors harbor KRAS mutations, with G12D being the most common (≈45‑51 %), followed by G12V and the rare G12C (<2 %). For decades KRAS was deemed "undruggable" because its shallow nucleotide‑binding site lacks druggable pockets and intracellular GTP concentrations are high, preventing effective small‑molecule engagement. The field shifted in 2018 when covalent G12C inhibitors (e.g., ARS‑1620, sotorasib, adagrasib) demonstrated that mutant‑specific pockets could be exploited, leading to FDA approvals for lung cancer and early PDAC trials. This breakthrough spurred a new generation of KRAS‑directed agents—including non‑covalent G12D inhibitors (MRTX1133, INCB161734), pan‑RAS ON‑state inhibitors (daraxonrasib), and allosteric degraders—redefining therapeutic strategies for KRAS‑driven pancreatic cancer.

KRAS Inhibitors: Examples and Mechanisms

Representative KRAS inhibitors

• KRAS G12C‑specific agents: sotorasib (Lumakras) and adagrasib (Krazati) are oral covalent inhibitors that bind the mutant cysteine at position 12, trapping KRAS in the GDP‑bound, inactive state. Both have FDA approval for KRAS‑G12C‑mutant non‑small‑cell lung cancer and are being studied in pancreatic cancer, where KRAS‑G12C occurs in <2% of cases.
• KRAS G12D‑selective molecules: MRTX1133, INCB161734, and zoldonrasib are non‑covalent or covalent inhibitors that engage the Switch‑II pocket of the G12D mutant, blocking downstream MAPK/PI3K signaling. Early‑phase trials in pancreatic ductal adenocarcinoma (PDAC) show disease‑control rates of 70‑80% and objective responses around 30‑40%.
• Pan‑RAS (ON‑state) inhibitors: daraxonrasib (RMC‑6236) and RMC‑7977 form ternary complexes that prevent KRAS‑RAF interaction while KRAS is GTP‑bound, achieving response rates near 27% in KRAS‑mutant PDAC.

Mechanism of small‑molecule KRAS inhibition All active inhibitors target a druggable pocket on KRAS—most often the Switch‑II pocket. Off‑state (GDP‑bound) agents such as sotorasib and adagrasib form a covalent bond to the mutant cysteine, locking KRAS in an inactive conformation and halting MAPK/PI3K signaling. Non‑covalent G12D inhibitors (e.g., MRTX1133) occupy the same pocket without a permanent link, stabilizing the inactive state while also engaging the GTP‑bound form. On‑state inhibitors (e.g., daraxonrasib) bind the active GTP‑bound KRAS and block effector binding, allowing inhibition even when KRAS is “on.”

Classification

• Off‑state inhibitors: covalent G12C agents (sotorasib, adagrasib) and non‑covalent G12D molecules that preferentially bind GDP‑KRAS.
• On‑state inhibitors: pan‑RAS ON‑state compounds (daraxonrasib, RMC‑6236) that target the GTP‑bound KRAS and prevent RAF interaction.

These strategies illustrate how diverse small‑molecule designs overcome the historic “undruggable” perception of KRAS, offering new therapeutic options for PDAC patients.

Current Landscape of KRAS‑Targeted Drugs in Pancreatic Cancer

KRAS‑directed therapy has moved from theory to clinic, but only two agents have received FDA approval to date. Sotorasib (Lumakras) and adagrasib (Krazati) are oral covalent inhibitors that bind the cysteine of KRAS G12C, locking the protein in an inactive GDP‑bound state. Sotorasib gained accelerated approval in 2021 for KRAS G12C‑mutant NSCLC and, in early 2025, was approved in combination with panitumumab for KRAS G12C‑mutant metastatic colorectal cancer. Adagrasib earned full approval in 2022 for the same NSCLC indication after prior systemic therapy. Both drugs require a companion diagnostic to confirm the G12C allele and are not indicated for the far more common KRAS G12D or G12V alterations in pancreatic ductal adenocarcinoma (PDAC).

In lung cancer, KRAS G12C inhibitors now constitute a standard line of therapy after platinum‑based chemotherapy and immunotherapy. Response rates hover around 30‑35 % with median progression‑free survival of ~6 months, but resistance via secondary KRAS mutations or bypass pathway activation emerges within 6‑8 months. Combination strategies—adding SHP2, MEK, or immune‑checkpoint inhibitors—are under active investigation to extend benefit.

Pancreatic cancer presents a distinct challenge: >90 % of PDAC harbor KRAS mutations, yet G12C accounts for only 1‑2 % of cases. Early‑phase trials of KRAS G12C inhibitors (e.g., sotorasib, adagrasib) report modest activity (ORR 10‑21 %) and disease‑control rates >80 % in heavily pre‑treated patients. More promising are mutation‑specific G12D inhibitors such as MRTX1133, INCB161734, and zoldonrasib which have shown objective response rates of 30‑45 % and disease‑control rates approaching 78 % in single‑agent and combination cohorts. These agents bind both GDP‑ and GTP‑bound KRAS G12D, overcoming the lack of a covalent cysteine and delivering rapid reductions in circulating tumor DNA allele frequency.

Colorectal cancer (CRC) also exhibits KRAS mutations in ~40‑45 % of cases. G12C‑mutant CRC (≈4 % of KRAS‑mutated CRC) now benefits from the same FDA‑approved inhibitors, with sotorasib + panitumumab and adagrasib + cetuximab achieving disease‑control rates >70 %. For the majority of KRAS‑mutant CRC lacking G12C, standard chemotherapy remains the backbone, and enrollment in trials of emerging G12D/V inhibitors or pan‑KRAS degraders is encouraged.

Overall, the field is transitioning from ‘undruggable’ to a rapidly expanding therapeutic landscape, with combination regimens, biomarker‑driven patient selection, and novel delivery platforms (nanoparticles, PROTACs poised to improve outcomes for KRAS‑driven pancreatic cancer.

Emerging Therapies for KRAS G12D and G12V in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is driven by KRAS mutations in >90 % of cases, with G12D accounting for roughly 45 % and G12V for about 30 % of KRAS‑mutant tumors. First‑in‑class G12D‑specific inhibitors such as MRTX1133 , INCB161734 , and zoldonrasib have moved from pre‑clinical proof‑of‑concept to early‑phase clinical evaluation. MRTX1133, a non‑covalent, Switch‑II pocket binder, has shown deep tumor regressions and increased CD8⁺ T‑cell infiltration in KRAS‑G12D mouse models and is now in a Phase 1/2 trial (NCT05737706). INCB161734, an oral molecule that binds both GDP‑ and GTP‑bound G12D, produced a 37 % objective response rate and 78 % disease‑control rate in heavily pre‑treated PDAC patients, with rapid ctDNA‑based molecular responses; a global Phase III DAWN‑303 trial is planned. zoldonrasib a a covalent ON‑state G12D inhibitor, reported a 30 % ORR in early PDAC data and received FDA breakthrough‑therapy designation for G12D‑mutant disease.

For G12V, no FDA‑approved small‑molecule exists yet. Current management relies on standard gemcitabine‑nab‑paclitaxel or modified FOLFIRINOX regimens, with trial enrollment encouraged. Investigational approaches include an RNA‑interference drug (EFTX‑G12V) that silences mutant KRAS via EGFR‑directed nanoparticles and a T‑cell‑receptor therapy (NW‑301V) that achieved a 42.9 % response rate in HLA‑A*11:01‑positive G12V patients. EGFR‑selective, mutation‑specific G12V inhibitors are in pre‑clinical development.

Combination strategies are now a cornerstone of KRAS‑targeted development. Pre‑clinical data demonstrate that pairing G12D inhibitors with gemcitabine‑nab‑paclitaxel or modified FOLFIRINOX yields synergistic tumor shrinkage, mitigates adaptive PI3K‑AKT up‑regulation, and improves drug penetration through the desmoplastic stroma. Early clinical cohorts of INCB161734 + gemcitabine/nab‑paclitaxel have reported manageable neutropenia and no dose‑interruptions.

KRAS inhibition also reshapes the immune microenvironment. MRTX1133 and INCB161734 increase tumor‑infiltrating CD8⁺ T cells, reduce myeloid‑derived suppressor cells, and elevate PD‑L1 expression, providing a rationale for combining KRAS inhibitors with checkpoint blockade. In murine models, KRAS‑G12D blockade plus anti‑PD‑1 produced durable regressions, and a pilot trial of KRAS‑G12D inhibitor plus pembrolizumab reported a 65 % disease‑control rate.

Answers to key questions:

• KRAS G12V mutation treatment: No approved small‑molecule; treatment relies on standard chemotherapy, immunotherapy when appropriate, and clinical‑trial enrollment (e.g., EFTX‑G12V siRNA, NW‑301V T‑cell therapy, EGFR‑directed G12V inhibitors in pre‑clinical stages).
• KRAS mutation lung cancer survival rate: Median overall survival for KRAS‑mutated NSCLC is ~12–15 months with conventional therapy; G12C‑targeted agents extend this to ~18–20 months, while other variants remain 10–13 months. Real‑world data show 11.2 months vs 14.6 months for KRAS‑wild‑type.
• KRAS mutation cancer: KRAS alterations occur in ~25 % of solid tumors, driving PDAC (85‑90 %), colorectal (~40 %), and NSCLC (~32 %). Mutations lock KRAS in an active GTP‑bound state, hyper‑activating MAPK and PI3K‑AKT pathways. G12C inhibitors have modest response rates (30‑40 %) with emerging resistance; newer agents target G12D/G12V, SOS1/2, or employ PROTAC degraders and combination regimens to overcome resistance and improve outcomes.

Clinical Trial Highlights and Combination Strategies

INCB161734 phase I/II data
In a recent phase I/II study presented at the 2026 ASCO GI Cancers Symposium, 41 heavily pre‑treated PDAC patients with KRAS G12D mutations received the oral inhibitor INCB161734 at 1,200 mg/day. Objective responses were observed in 15 patients (37 %) and disease control was achieved in 32 patients (78 %). Median follow‑up of five months showed not yet reached progression‑free survival, and ctDNA analyses demonstrated ≥90 % allele‑frequency reductions in two‑thirds of evaluable patients. Combination cohorts with gemcitabine + nab‑paclitaxel and modified FOLFIRINOX were feasible, with neutropenia the most common grade ≥ 3 toxicity.

MRTX1133 pre‑clinical and early clinical findings
MRTX1133 is a non‑covalent, selective KRAS G12D inhibitor that binds both GDP‑ and GTP‑bound KRAS. Pre‑clinical models showed >30 % tumor regression in 73 % of KRAS G12D PDAC cell lines and xenografts, and murine studies reported rapid tumor‑infiltrating CD8⁺ T‑cell expansion. Early‑phase clinical data (NCT05737706) have demonstrated partial responses and disease stabilization in patients with KRAS G12D‑mutant pancreatic cancer, with a manageable safety profile dominated by low‑grade gastrointestinal events.

Daraxonrasib (RMC‑6236) phase III outcomes
Daraxonrasib (RMC‑6236) a a pan‑KRAS ON‑state tri‑complex inhibitor, has entered a global phase III trial (RASolute 302) comparing it to standard chemotherapy in metastatic PDAC. Interim data show a median progression‑free survival of 8.5 months and an overall response rate of 27 % across KRAS‑mutant cohorts, with disease control rates exceeding 85 %. The drug’s ability to bind multiple KRAS isoforms (including G12D, G12V, and G12C) offers a broad therapeutic window for KRAS‑driven pancreatic tumors.

Rationale for combining KRAS inhibition with chemotherapy, immunotherapy, and stroma‑targeting agents
KRAS inhibition alone often leads to adaptive resistance via PI3K‑AKT up‑regulation, MET amplification, or EGFR feedback. Combining KRAS inhibitors with standard chemotherapy (gemcitabine + nab‑paclitaxel or FOLFIRINOX) synergistically enhances tumor cell death and may reduce stromal density, improving drug penetration. Immunotherapy combinations (e.g., anti‑PD‑1/PD‑L1) are promising because KRAS blockade can increase tumor antigen presentation and CD8⁺ T‑cell infiltration, as demonstrated in MRTX1133 mouse models. Moreover, anti‑fibrotic strategies (nanoparticle delivery, anti‑FAP antibodies) address the dense desmoplastic stroma that limits drug access in PDAC.

Is KRAS mutation good or bad?
KRAS mutations are generally a negative prognostic factor, locking the growth switch “on” and driving aggressive disease. Yet they also create a therapeutic target; specific inhibitors (e.g., sotorasib for G12C, MRTX1133 for G12D) provide a path toward personalized treatment, turning a “bad” biology into a “good” opportunity for targeted therapy.

KRAS inhibitors review
KRAS inhibitors are small‑molecule agents that bind mutant KRAS proteins. Approved G12C inhibitors (sotorasib, adagrasib achieve 30‑40 % response rates but face resistance via secondary mutations and bypass pathways. Combination regimens with chemotherapy, checkpoint inhibitors, or SHP2/MEK inhibitors are under investigation to prolong benefit.

KRAS inhibitors small molecules
All clinically approved and investigational KRAS inhibitors are small molecules. They exploit pockets in the Switch‑II region (covalent G12C) or engage non‑covalent sites (G12D, G12V) to lock KRAS in an inactive conformation or disrupt downstream signaling. Emerging PROTAC degraders also rely on small‑molecule KRAS‑binding ligands.

Impact of KRAS Mutations on Prognosis and Life Expectancy

KRAS mutations dominate the genomic landscape of pancreatic ductal adenocarcinoma (PDAC), being present in >90 % of cases and driving a dismal five‑year survival of only 6‑10 % (PDAC). In the metastatic setting, KRAS‑mutant disease confers a markedly shorter overall survival (OS) than KRAS‑wild‑type counterparts. For example, patients with KRAS‑G12C‑mutant PDAC treated with sotorasib achieved a median OS of 6.9 months, while adagrasib yielded an OS of 8 months. Newer G12D‑directed agents such as INCB161734 and daraxonrasib have raised median OS to 14‑15 months in heavily pre‑treated and second‑line cohorts, respectively, but still fall short of curative expectations.

In non‑small‑cell lung cancer (NSCLC), KRAS‑mutated tumors historically showed a median OS of 12‑15 months with standard therapy. The introduction of G12C‑specific inhibitors (sotorasib, adagrasib has extended median OS to 18‑20 months in clinical trials, though real‑world data still average ~11 months. Other KRAS subtypes (G12D, G12V) remain less responsive, with survival around 10‑13 months.

Overall, the presence of a KRAS mutation signals a poorer prognosis across solid tumors. Median survival varies by cancer type and line of therapy—approximately 24‑39 months in KRAS‑mutant metastatic colorectal cancer, 12‑15 months in KRAS‑mutant NSCLC, and 14‑15 months in KRAS‑mutant PDAC when treated with next‑generation inhibitors. Emerging combination strategies (KRAS inhibitor + chemotherapy, immune checkpoint blockade, or stroma‑targeting agents) aim to improve these outcomes, but current data still reflect a modest but measurable reduction in life expectancy compared with KRAS‑wild‑type disease.

Future Directions: Nanoparticles, PROTACs, and Immunotherapy

Pancreatic ductal adenocarcinoma (PDAC) is driven by KRAS mutations in >90% of cases, making the oncogene a pivotal therapeutic target despite its historical reputation as “undruggable”. The mutation itself is a negative prognostic factor because it locks the signaling switch in an onc “on” state, fostering aggressive growth and immune evasion. At the same time, the presence of a KRAS alteration creates a precise druggable vulnerability – covalent G12C inhibitors (sotorasib, adagrasib) and emerging G12D agents (MRTX1133, INCB161734) have demonstrated clinical activity, and RNA‑based or SOS‑protein approaches are under investigation for other subtypes.

Nanoparticle delivery to overcome PDAC stroma – The dense desmoplastic matrix of PDAC impedes drug penetration. Nanoparticle formulations of gemcitabine (chitosan, gold, albumin) and of KRAS inhibitors (e.g., albumin‑bound MRTX1133 have increased intratumoral concentrations and antitumor efficacy in pre‑clinical models, offering a strategy to bypass physical barriers.

PROTAC degraders targeting KRAS – New PROTAC molecules (e.g., DJX‑A‑KM for G12C, bifunctional PROTACs for G12D) recruit E3 ligases such as FBXO28 or VHL to mutant KRAS, inducing ubiquitination and proteasomal degradation. Early studies show sustained KRAS knock‑down and superior tumor regression compared with inhibition alone, representing a novel mechanism beyond pocket binding.

Synergy between KRAS inhibition and immune checkpoint blockade – KRAS inhibition remodels the tumor immune microenvironment, increasing CD8⁺ T‑cell infiltration and reducing myeloid‑derived suppressor cells (https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1223433/full). Combination trials of KRAS G12C inhibitors with anti‑PD‑1/PD‑L1 antibodies have yielded higher response rates and deeper tumor regressions in mouse models, and early‑phase pancreatic trials are now testing G12D inhibitors (MRTX1133, INCB161734 together with pembrolizumab.

Impact of KRAS mutation on tumor immune microenvironment – KRAS‑mutant PDAC typically exhibits low PD‑L1 expression and a suppressive cytokine milieu (CXCL1/2/5, TGF‑β, IL‑10) (https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1223433/full). Direct KRAS blockade reverses these features, up‑regulating antigen presentation and making tumors more amenable to immunotherapy. Thus, integrating nanoparticle delivery, PROTAC degradation, and checkpoint inhibition holds promise for overcoming both molecular and stromal resistance in KRAS‑driven pancreatic cancer.

Outlook

The next phase of pancreatic cancer therapy will hinge on weaving KRAS‑targeted agents into existing treatment algorithms. Early‑phase data with KRAS‑G12D inhibitors such as MRTX1133, INCB161734, and the pan‑RAS molecule daraxonrasib demonstrate objective responses and disease‑control rates that rival standard chemotherapy, especially when combined with gemcitabine‑nab‑paclitaxel or FOLFIRINOX. Consequently, guideline‑endorsed biomarker testing for KRAS subtypes is becoming a prerequisite for therapy selection, and trials now prioritize first‑line KRAS‑inhibitor plus chemotherapy arms. Participation in these studies is critical; patients gain access to cutting‑edge drugs while contributing data that refine dosing, resistance‑management, and biomarker‑driven enrollment criteria. Hirschfeld Oncology is actively enrolling eligible patients, offering comprehensive genomic profiling, multidisciplinary care, and supportive services. By aligning precision medicine with compassionate, team‑based management, Hirschfeld aims to translate KRAS advances into tangible survival gains for pancreatic cancer patients.